TARGET FOR IQ · CURRENT AFFAIRS
NPPA’s Anti-Cancer Drug Price Monitoring: 137 Medicines and November 2026 Dates
Current affairs reading · 2 min read · English
On this page
What is the update?
NPPA directed closer monitoring of trade-margin rationalisation for 137 non-scheduled anti-cancer medicines. The update concerned implementation of revised prices and their display, with State Drug Controllers responsible for checking compliance.
The key dates
| Stage | Date |
|---|---|
| Gazette order | 17 October 2026. |
| Revised prices effective | 9 November 2026. |
| Company submissions used for the published lists | Up to 11 November 2026. |
| Monitoring announcement | 13 November 2026. |
| Action Taken Reports requested from states | By 16 November 2026. |
What the direction required
Manufacturers, retailers, dealers, stockists, hospitals and medical institutions were directed to follow the revised prices and display updated lists on their premises and websites. NPPA identified its website and Pharma Sahi Daam as places to access the lists. It stated that violations could lead to overcharging proceedings under DPCO, 2013.
Why implementation matters
Publishing a revised price and ensuring that the price is reflected at the point of sale are separate administrative steps. Display requirements can make the applicable information easier to see, while monitoring examines whether the rules are actually being followed.
Trade-margin rationalisation concerns the pricing chain. It is not an announcement that a medicine has gained a new clinical indication, nor does the figure 137 mean that 137 new cancer treatments were discovered. The medicine count describes the scope of this pricing action.
Exam revision approach
Organise this update around the regulator, coverage, effective date and compliance responsibility. Keep the Gazette date separate from the date revised prices took effect. Similarly, the deadline for officials to submit a report is not a new commencement date for the prices.
The announcement supplied no single retail price for every covered medicine. A medicine-specific price cannot be inferred from the number of products under monitoring, and this update should not be read as a recommendation to choose or change treatment.
Exam revision
- NPPA: National Pharmaceutical Pricing Authority, under the Department of Pharmaceuticals.
- Coverage: 137 non-scheduled anti-cancer medicines.
- Revised prices took effect on 9 November 2026.
- State reports were requested by 16 November.
Quick questions
Was this a new medicine approval?
No. It concerned implementation of a pricing measure.
Which date governed the revised prices?
9 November 2026, distinct from the October Gazette order and the later reporting deadline.
Official references: Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals — 2026-11-13.